



Takeda legal Entity: Takeda Pharma Vertrieb GmbH

Takeda GmbH

EFPIA Disclosure Code Sub-certification statement to create support for the EFPIA self-certification

Healthcare professionals (HCPs) and organisations (HCOs), with whom Takeda Pharma Vertrieb GmbH works, provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience.

Takeda Pharma Vertrieb GmbH believes that interactions between pharmaceutical companies and healthcare professionals – either directly or through healthcare organisations – have a profound and positive influence on the quality of patient treatments and value of future research.

The European Federation of Pharmaceutical Industries Associations (“EFPIA”) and its member associations have adopted codes and guidelines to ensure that the interactions meet the high standards of integrity that patients, governments and other stakeholders expect.

Because the society has a growing expectation that interactions between corporations & healthcare professionals and organisations are not only conducted with integrity but are also transparent, Takeda Pharma Vertrieb GmbH discloses transfers of values made to healthcare professionals and organisations in due respect of EFPIA Disclosure code’s requirements.

All individual data published in our disclosure has been made with the support of healthcare professionals and organisations.

Takeda Pharma Vertrieb GmbH complies with the local disclosure legislation or regulations, where applicable and commits to apply EFPIA Disclosure Codes provisions and especially the following key principles.

a) Disclosure quality (fair and complete)

Takeda Pharma Vertrieb GmbH certifies that:

- This disclosure includes direct and indirect Transfers of Values (ToVs) with definitions in line with the Disclosure code’s requirement.
- In case our company operates also via distributor, Takeda Pharma Vertrieb GmbH undertakes actions for disclosure of ToVs made on behalf of Takeda Pharma Vertrieb GmbH
- Its methodological note explains decisions related to the Disclosure.

b) Methodology used for the collection and organisation of ToVs are in line with EFPIA Code’s Requirements

Takeda Pharma Vertrieb GmbH certifies that:



- Data collection complies with Disclosure code's requirement, especially in the consent collection.
- Actions were put in place to gain consent from HCPs (and HCOs where applicable).

c) Aggregate disclosures are limited to R&D and ToVs where information cannot be disclosed on an individual basis for legal reasons

Takeda Pharma Vertrieb GmbH warrants that aggregate disclosure is limited to the following topics:

- Research & Development (R&D) data (with an exclusion of the non-interventional studies which are retrospective).
- HCPs and HCOs (where applicable) data in case of non-positive consent for individual disclosure.
- If an HCP and an HCO (where applicable) chooses to grant only partial consent, Takeda Pharma Vertrieb GmbH will disclose all ToVs to such HCP (HCO where applicable) in aggregate.

d) Provided efforts on gaining consent of Recipients

Takeda Pharma Vertrieb GmbH warrants that it has made its best efforts in seeking consent from HCPs and HCOs (where applicable) for individual disclosure.

Date: 30 / May /2017

Name of signatory: Günter Kloucek

Title of Signatory: GM, Speaker of Management Board

Signature:

Note: This sub-certification scheme will provide the base for the self-certification scheme to be signed by TAKEDA EUCAN President.